Borcherding, Nicholas

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2

Amanat, F., Thapa, M., Lei, T., Ahmed, S. M. S., Adelsberg, D. C., Carreño, J. M., Strohmeier, S., Schmitz, A. J., Zafar, S., Zhou, J. Q., et al. (2021) · Cell

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 273

Obesity-associated NLRC4 inflammasome activation drives breast cancer progression

Kolb, R., Phan, L., Borcherding, N., Liu, Y., Yuan, F., Janowski, A. M., Xie, Q., Markan, K. R., Li, W., Potthoff, M. J., et al. (2016) · Nature Communications

Inflammasome and immune disordersImmune cells in cancer

Cited by 239

Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors

Vikas, P., Borcherding, N., Chennamadhavuni, A., & Garje, R. (2020) · Frontiers in Oncology

PARP inhibition in cancer therapyCancer Immunotherapy and Biomarkers

Cited by 179

Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade

Lander, V. E., Belle, J. I., Kingston, N. L., Herndon, J. M., Hogg, G. D., Liu, X., Kang, L.-I., Knolhoff, B. L., Bogner, S. J., Baer, J. M., et al. (2022) · Cancer Discovery

Pancreatic and Hepatic Oncology ResearchCancer Immunotherapy and Biomarkers

Cited by 114